Introduction
A major aim of in vivo gene transfer strategies is to direct gene delivery to a specific target tissue. In this respect the ideal gene delivery system has to fulfil several properties. First, because of biophysical requirements and anatomical constraints (such as migration through blood capillaries, extravasation through small vascular fenestrations, diffusion into tissue, cellular uptake) transfection particles should be small, without a tendency to aggregate before or during in vivo application. Second, unspecific interactions of transfection particles with the biological environment should be minimal. For intravenous administrations, undesired interactions (of the vector) with blood components and non-target cells such as the reticuloendothelial system (RES) are important obstacles in targeting genes in vivo. The opsonization of foreign particles with plasma proteins actually presents one of the first steps in the natural process of removal of foreign particles by the innate immune system. It has been reported that the amount of plasma bound to liposomes correlates with their unspecific clearance from blood after intravenous injection. 1 To reduce protein binding to liposomes, hydrophilic polymers such as poly(ethylene glycol) (PEG) 2, 3 or other hydrophilic polymers 4, 5 have been coupled to lipids. These modifications have been shown to prolong the half-life in blood.
Correspondence: E Wagner, Institute of Biochemistry, Vienna University Biocenter, Dr. Bohrgasse 9/3, A-1030 Vienna, Austria Received 6 October 1998; accepted 21 December 1998 DNA/polyethylenimine (PEI) complexes display high transfection efficiency in cell culture and also have potential for in vivo gene delivery. [6] [7] [8] In approaches to optimize further this system for in vivo applications, coupling of cell-binding ligands 9, 10 and complex formation under low ionic conditions to generate small DNA/PEI particles for improved diffusibility [11] [12] [13] have been described. In the current work we studied the interaction of DNA/transferrin-PEI complexes with blood components. As demonstrated here, by covalent surface modification of the complexes with PEG the unspecific interactions with plasma proteins and erythrocytes can be reduced. We also describe additional positive consequences of PEGylation, both on the biophysical properties and the in vivo properties upon systemic application.
Results
Physicochemical properties of PEGylated DNA/TfPEI complexes The PEGylation was carried out after complexing plasmid DNA with transferrin-PEI (TfPEI) or PEI (PEI 800 kDa, Fluka). We applied this strategy (instead of using PEGylated PEI for complex formation) in order to prevent any undesired effect of PEG-modified polycations on the DNA condensation process. 14 Covalent coupling of PEG has been carried out via the primary amino groups in the PEI molecules by reaction with the succinimidyl derivative of PEG propionic acid poly(ethylene glycol) with a molecular weight of 5000 Da (M-PEG-SPA 5000). Analysis of primary amino groups by ninhydrin assay 15 has shown that approximately every third to fourth nitrogen of PEI is a primary amine (data not shown). In most experiments a standard w/w ratio of M-PEG-SPA 5000 and TfPEI of 10/1 was used (this corresponds to a molar ratio of approximately one molecule M-PEG-SPA 5000 per three primary amino groups of PEI) and the reaction was carried out at room temperature for 1 h. Ninhydrin-assay (measuring the decrease of primary amino groups) confirmed that the reaction was complete, and approximately one-third of the primary amino groups were modified with PEG. Size and shape of the PEGylated complexes was checked by electron microscopy. 13 The majority of DNA/TfPEI and DNA/TfPEI/PEG complexes generated under conditions of low salt (HEPES-buffered glucose, HBG) appeared as spherical particles with a diameter of 40 nm, with only a few larger complexes; there was no change after PEGylation (data not shown).
It has been reported that the hydrophilic polymer on the surface of liposomes can protect from salt-induced aggregation ('steric stabilization'). 16 In an analogous fashion we tested whether PEG coating sterically stabilizes the DNA/TfPEI complexes in size (Figure 1 ). DNA and TfPEI were mixed under salt-free conditions 13 and the surface of complexes was modified with M-PEG-SPA 5000 as described above. After 1 h of reaction an aliquot of phosphate-buffered saline (PBS) was added. To measure aggregation of the complexes, particle sizes were determined at the indicated time-points by quasi-elastic (dynamic) light scattering (QELS). DNA/TfPEI/PEG complexes showed no increase in the mean particle size; however, a rapid aggregation of particles was observed with non-PEGylated complexes (Figure 1 ). The same effect of PEGylation was obtained with PEI instead of TfPEI (data not shown). To check whether the stabilization requires covalent coupling of PEG, in a control group PEG molecules without reactive linker were added to DNA/TfPEI complexes. In this case a rapid aggregation of the DNA particles occurred. PEI conjugates without DNA did not form any measurable particles in the absence or presence of PBS.
For in vivo applications highly concentrated solutions of DNA complexes are usually required. Increasing the concentration of DNA and PEI during complex formation above 50 g DNA/ml results in formation of aggregates. 13 For this reason we explored whether dilute DNA/TfPEI complexes (with or without PEGylation) can be concentrated by ultrafiltration. Complexes were mixed at a DNA concentration of 20 g/ml under salt-free conditions, (optionally) PEGylated, and concentrated on microconcentrators to 400 g/ml DNA (see Materials and methods). Recovery and size of particles were measured by UV absorption at 260 nm and QELS. Approximately 90% of the PEGylated complexes were recovered. PEGylated complexes were still small, without significant increase in average diameter (as determined by QELS, 93 nm before versus 120 nm after concentration). In the case of non-PEGylated complexes, approximately twothirds of the DNA was lost after concentration (data not shown).
The surface charge of gene transfer particles seems to be an important factor for in vivo delivery. An excess of positive charge, among other consequences, can strongly activate the complement system. 17 We investigated the effect of PEG modification of DNA/PEI complexes on the surface charge by measurement of the zeta potential ( Figure 2 ). DNA complexes with PEI or TfPEI were formed at different N/P charge ratios and PEGylated. In all cases electroneutrality of complexes appears at approximately N/P ratio of 2. Agarose gel mobility shift assays also showed that the DNA is completely retarded above N/P 2 (data not shown). When comparing DNA/PEI and DNA/TfPEI complexes, at N/P у3 a significantly reduced surface charge is measured for DNA/TfPEI complexes as compared with DNA/PEI complexes. Two possible causes can explain this effect. On the one hand, the negatively charged Tf can compensate for the positive charges of PEI. On the other hand, the serum protein Tf on the surface of the complex can shield some of the positive PEI surface charges. After PEGylation of either DNA/PEI or DNA/TfPEI complexes, an additional reduction of the surface charge is observed, which is consistent with the previously known shielding effect of PEG. In particular, PEG-modified DNA/TfPEI complexes possess an almost charge-free surface in a broad N/P range between 2 and 6.
Interactions of DNA/TfPEI complexes with blood components Previous work in our laboratory 13 has shown that serumfree cell culture medium -similar to salt -can rapidly aggregate DNA/TfPEI complexes, whereas medium containing 10% FCS stabilizes the complexes. Plasma, which (in contrast to fetal serum) contains the proteins of the coagulation cascade, has a different effect ( Figure 3 ). Complexes were incubated with diluted plasma and the respective size was measured by QELS. Non-PEGylated complexes form aggregates with plasma proteins; in contrast, PEG-modified complexes remain small and unaggregated. To rule out the possibility that the citrate contained in the plasma was responsible for aggregation of complexes, in a control experiment the complexes were incubated with comparable amounts of sodium citrate without plasma. In this case no aggregation was observed with DNA/TfPEI or DNA/TfPEI/PEG complexes (data not shown).
To identify the plasma proteins bound to the complex, a filtration assay was performed ( Figure 4 ). Complexes were prepared as described in Materials and methods. After incubating the complexes in diluted human or mouse plasma, the mixtures were filtered on microcentrifuge tube filters. Unbound plasma proteins ('filtrates') and DNA complex/protein aggregates recovered by dissolving in SDS ('eluates') were applied on to a SDS gel. Proteins were stained or blotted on to a nitrocellulose membrane and immunologically identified. As shown in Figure 4a (mouse plasma) and Figure 4b (human plasma), distinct proteins of molecular weight Ͼ150 kDa bind to the non-PEGylated complexes (see eluates). The major proteins have been identified by Western blot as IgM, fibronectin, fibrinogen and complement C3 (see labels in Figure 4b ). Figure 4c shows blots for human IgM (upper panel) and human complement C3 (lower panel). When looking at PEGylated complexes, a strong reduction in binding of plasma proteins was found with both murine and human plasmas. A similar pattern of bound proteins was found with complexes incubated in 50% human plasma. Again, after PEGylation of complexes a strong reduction in protein binding was observed. Non-covalently bound PEG did not prevent protein binding (data not shown).
To investigate the interaction of DNA/TfPEI complexes with erythrocytes, an erythrocyte aggregation assay was performed ( Figure 5 ). Mouse erythrocytes were incubated with either PEGylated or non-PEGylated DNA/TfPEI complexes (N/P 6.0). After 1 h of incubation at 37°C aggregates consisting of several to many erythrocytes could be observed (Figure 5b ). In the case of PEGylated complexes this aggregation was strongly reduced (Figure 5c ). No aggregation was observed in the control (Figure 5a ). Similar findings were made with whole murine citrate blood. The N/P charge ratio has a significant influence on aggregation. No erythrocyte aggregation was observed with PEGylated complexes at N/P 4.8, but significant aggregation was observed at N/P 7.2 (data not shown).
PEGylation of DNA/TfPEI complexes does not interfere with transfection in vitro
To test in vitro gene transfer, the human cell line K562 was chosen. This cell line displays a high level of transferrin receptors and is efficiently transfected via transferrin receptor-mediated gene delivery. 9, 18 Cells were transfected with small DNA complexes of TfPEI (or PEI) generated in HBG (Figure 6a , left bars) or large DNA complexes generated in Hepes-buffered saline, HBS ( Figure 6a , right bars). PEGylated and non-PEGylated complexes were tested. Consistent with our previous work, 13 the larger HBS complexes resulted in higher transfection efficiencies than the small HBG complexes, and transferrin-containing complexes showed higher efficiencies than transferrin-free complexes. PEGylation did not interfere with the transfection activity. Transfection efficiency with the PEGylated TfPEI containing complexes remained at the same levels, and only a slight reduction in the group of DNA/PEI complexes formed in HBG (Figure 6a , left bars) was observed. A significant reduction in transferrin-mediated gene transfer was only obtained at PEI/PEG rations above 14/1 w/w (data not shown). Similar findings were made using the Neuro2A tumor cell line ( Figure 6b ) where PEGylation did not significantly change the expression profile of TfPEI/DNA complexes. Expression levels increased with the ionic strength during complex formation (HBS Ͼ 0.5 × HBS Ͼ HBG).
Figure 4 Reduced interaction of different plasma proteins with complexes after PEGylation. A filtration assay was performed as described in Materials and methods to investigate the binding of DNA/TfPEI complexes with mouse (a) or human (b and c) plasma proteins. (a) and (b) show silver stains, (c) shows Western blots for human IgM (upper blot) and human complement C3 (lower blot) using the analogous

Circulation of complexes in blood
It has already been described that incorporation of PEG into liposomes can increase their half-life in blood 3, 19 (reviewed in Ref. 20) . For this reason we investigated the effect of PEGylation of DNA/TfPEI complexes on their persistence in blood by injecting the complexes (containing 50 g pCMVL DNA) into the tail vein of A/J mice ( Figure 7 ). After 30 min and after 2 h blood was collected, and the amounts of plasmid DNA in blood and plasma were determined by Southern blot analysis. NonPEGylated DNA/TfPEI complexes are rapidly cleared from blood. After 30 min approximately 6% of the injected DNA dose is still detectable (Figure 7a , left panel), but only less than 0.5% of the plasmid can be detected in the cell-free plasma fraction (Figure 7b , left panel). This finding is consistent with binding to erythrocytes (see Figure 5) .
DNA/TfPEI/PEG complexes ( Figure 7a and b, right panels) show prolonged circulation in the blood stream. Thirty minutes after injection approximately one-third of the injected dose was still detected in plasma or whole blood. After 2 h a small amount of DNA can still be found in whole blood (approximately 3%), and, to a lesser extent, in plasma (approximately 1%). The Southern blot analysis discriminates between intact plasmid and smaller fragments of pCMVL. The major fraction of the recovered plasmid was not degraded. This indicates that the complexed DNA was protected from nucleases in blood.
Transfection properties in vivo
To investigate whether the blood circulation period of DNA/TfPEI/PEG complexes is sufficient to reach a specific target tissue such as a distantly growing tumor, we With the small PEGylated complexes generated in water (Figure 8a) , in most organs a low (liver) or negligible gene expression was observed. However, significant expression levels were found at the injection site and in the tumor. The small DNA complexes were well tolerated without visible toxicity. Cell culture experiments have shown that larger DNA complexes (generated at higher salt concentration) have higher transfection activity (see Figure 6 and Ref. 13 ). To achieve higher in vivo gene expression levels, we tested PEGylated DNA complexes that were generated in 0.5 × HBS (Figure 8b ). The medium salt concentration was used to achieve slightly larger complexes, but to avoid the formation of large aggregates (PEGylated aggregated complexes formed in HBS and applied at a 50 g DNA dose are highly toxic; data not shown). Using these complexes, a 10-fold increase in tumor expression (Figure 8b ) was obtained in comparison to complexes used in Figure 8a . When 50 g of non-PEGylated DNA complexes (generated in 0.5 × HBS) were injected, a high acute toxicity was observed: 50% of the animals died within 30 min after injection, most probably because of a block of the lung vasculature. Moreover, the gene expression pattern in surviving animals differed from mice treated with PEGylated complexes. The highest levels of gene expression were found in the lung and at the injection site, whereas only low levels of expression could be measured in the other organs including the tumor (Figure 8c ). 
Discussion
Intravenous application of larger material such as liposomes or polymer particles is often accompanied by unspecific interactions with blood. The opsonization of particles with plasma proteins triggers a rapid clearance by cells of the RES. 1, [21] [22] [23] [24] [25] These undesired interactions have to be avoided in order to deliver pharmaceutically active particles to certain target tissues. Hydrophilic polymers such as poly(ethylene glycol) (PEG) have been used for this purpose. 19, 26 Shielding the surface of liposomes by PEG strongly increased their circulation time in blood. It was also possible to include receptor binding moieties such as antibodies into these shielded liposomes to target certain tissues 27, 28 including tumors 29 ('active targeting'). Furthermore, because of the leakiness of the tumor vasculature 30 also non-targeted PEGylated liposomes can accumulate in solid tumors 31, 32 ('passive targeting'). Here we describe the PEGylation of DNA/transferrin-PEI complexes. To allow proper condensation of the DNA with the polycation, the covalent coupling of PEG was performed after complex formation (see Figure 9 ). The modification with PEG notably changes the characteristics of the DNA particles: it stabilizes particles against aggregation, allows ultra-concentration of particles (to up to 1 mg/ml of DNA) and strongly reduces the surface charge. This shielding of the particle surface also blocks the interactions with plasma proteins and erythrocytes. PEGylation does not interfere with in vitro transfection activity and still allows the interaction of a complex-linked ligand with its cell-surface receptor (transferrin was used as ligand, as described in this work; analogous findings were made with epidermal growth factor; our unpublished data). In addition, these biophysical properties translate into a prolonged circulation in the blood of treated animals and a systemic gene delivery to a distant target site (see below).
Figure 9 PEGylation of DNA/TfPEI particles after complex formation results in shielding from unspecific interactions with blood but allows ligandspecific interaction with the cell surface receptor.
The charge of DNA complexes appears as an essential factor for interaction with blood and for in vivo gene delivery. 33 Using cationic liposome/protamine/DNA complexes, Li and colleagues 34 showed that an initially positive surface charge of complexes upon interaction with plasma changed into a negative charge due to association with plasma proteins. Positively charged DNA complexes can activate the alternative complement pathway. 17 DNA/PEI complexes with a PEI nitrogen: DNA phosphate (N/P) ratio of Ͼ3 have a strongly positive surface charge (as presented here and in Ref. 35) . Although incorporation of PEI-conjugated transferrin into the DNA complexes significantly reduces the surface charges, a positive surface charge still remains at N/P ratios around 6 (which is most efficient for in vitro transfection). When incubating DNA/TfPEI (or PEI) complexes with plasma, aggregation of particles was observed; we found that fibronectin, fibrinogen, complement factor C3 and IgM bind to the complexes. In sharp contrast, PEGylated complexes do not bind these proteins and do not aggregate.
Standard DNA/TfPEI complexes can also interact with erythrocytes. In an in vitro assay we showed that by mixing them with whole blood or washed erythrocytes, aggregation of erythrocytes was seen. McLean and colleagues 36 who observed binding of cationic liposome/DNA complexes to red blood cells made related findings. PEGylated DNA/TfPEI complexes (at N/P ratios of Ͻ6) were not found to aggregate erythrocytes; however, significant aggregation was observed at a higher charge ratio of N/P 7.2.
The interaction of DNA complexes with blood components has major consequences for intravenous gene delivery. For example, when cationic lipid-based DNA complexes are injected into the tail vein of mice, the delivered DNA appears mainly in the lung, liver and spleen. 20, [37] [38] [39] [40] [41] The highest gene expression is found in the lung; this fact is considered to result from aggregation of complexes with plasma proteins 34 followed by retention in the first capillary vascular bed that the aggregate encounters. 34 Similarly, upon injection of standard DNA/TfPEI complexes (50 g DNA) significant expression was found only in the lung (and at the application site) but in no other distant organ. The application of these nonPEGylated complexes was accompanied by a high acute toxicity (within the first hour) with signs of acute lung embolism resulting in up to 50% lethality of treated mice, the assumption being that the block of lung vasculature results from aggregates formed by DNA complexes interacting with plasma proteins and/or erythrocytes. This is consistent with the observation that the application of larger DNA complexes (generated in salt buffer) show higher lethality (approximately 50%) than small DNA complexes formed in water (approximately 15%, data not shown). Further parameters such as the charge ratio (see below) or the type of PEI polymer influence lethality. We used a branched PEI polymer of 800 kDa; recently, data with a linear PEI (22 kDa) polymer which can mediate gene transfer to the lung without lethality have been described. 42 To study the in vivo properties of the PEGylated DNA/TfPEI complexes, we investigated their retention time in blood after tail vein injection. Approximately onethird of the injected DNA dose was found in plasma after 30 min, and after 2 h still a low, but significant amount of plasmid DNA was detected. Furthermore, PEGylated complexes at N/P р6 were well tolerated, without lethality. Only at a higher N/P ratio of 7.2, when complexes also show in vitro aggregation of erythrocytes is toxicity observed. In contrast, no significant amounts of DNA were detected in plasma after 30 min with unmodified DNA/TfPEI complexes.
Although the circulation of the PEGylated complexes is quite short in comparison to circulation times described for PEGylated liposomes, 3 within this period the blood will circulate through the body many times. A 'short-term' circulation should be sufficient for DNA complexes to actually reach the tumor through the vascular route (instead of being cleared by lung endothelium and the RES). To test whether this can result in successful gene transfer into a distant target tissue, the PEGylated complexes were injected into the tail vein of mice carrying subcutaneous neuroblastoma tumors. Indeed, gene expression was found at the injection site and in the tumor, but not in significant levels in other organs. Using small DNA/TfPEI particles generated in water, the expression levels were quite low. This might result from the fact that these small particles are far less effective in gene transfer compared with the large aggregates. 13 In vitro data have shown that with a moderate increase in the ionic strength of the complexation solution (NaCl concentration of 75 mm), partially aggregated particles with a medium size of 200-400 nm can be generated which also show an intermediate in vitro transfection activity. With these particles a 10-fold increase in in vivo tumor expression was achieved. An increased expression in the lung was also observed. However, in contrast to the non-PEGylated complexes, no acute toxicity was observed in any mice.
Taken together, our findings re-enforce the importance of biophysical analysis of gene transfer particles for in vivo administrations. Modification of the surface of DNA complexes with PEG blocks the interactions with plasma components and erythrocytes. This procedure strongly changes the in vivo characteristics of particles, resulting in reduced toxicity, prolonged circulation, and gene expression in distant tumor tissue after systemic administration. For practical application, further improvements of the gene delivery system have to be made. Beside the optimization of the carrier molecule, the introduction of endosomolytic functions, 43 target tissue-specific ligands 44 or nuclear transport domains 45 are considered to achieve the goal of an effective, directed gene transfer in vivo for successful gene therapies.
Materials and methods
Chemicals Polyethylenimine (PEI, 800 kDa) was obtained from Fluka (Buchs, Switzerland) as a 50% w/v solution. The solution was titrated with HCl solution to a pH of 7.4 and used as a 9 mg/ml stock and 1 mg/ml working solution. Synthesis of TfPEI conjugates was described in Kircheis et al. 9 In general, a TfPEI conjugate with a molar ratio of approximately four transferrin molecules linked to PEI 800 kDa was used. Transfections of K562 cells were performed with a TfPEI conjugate containing two Tf molecules per PEI molecule. M-PEG-SPA 5000 with an average molecular weight of 5000 Da was obtained from Shearwater Polymers (Huntsville, AL, USA) and used as a 20 mg/ml stock solution in water-free dimethylsulfoxide (DMSO). PEG MW 6000 was obtained from Merck (Darmstadt, Germany). Human and mouse citrate plasma were obtained from Sigma (St Louis, MO, USA).
Complex formation DNA/TfPEI complexes at the indicated N/P ratios (eg 10 g DNA with 1.88 g (N/P 1.5), 3.75 g (N/P 3.0) or 7.5 g (N/P 6.0) of (Tf)PEI) were mixed at the indicated DNA concentration. The TfPEI solution was pipetted to the DNA solution and immediately mixed by pipetting up and down. Plasmid pCMVL, coding for the Photinus pyralis luciferase gene under control of the cytomegalovirus enhancer/promoter, has been described in Plank et al. 46 The endotoxin-free DNA was dissolved in 20 mm Hepes pH 7.4. Complexes were mixed in water, HBG (20 mm Hepes pH 7.4, 5% glucose w/v), HBS (145 mm NaCl, 20 mm Hepes pH 7.4) or 0.5 × HBS (75 mm NaCl, 10 mm Hepes pH 7.4). To ensure iso-osmolarity, for transfection experiments and in vivo applications glucose was added to a final concentration of 5% (water) or 2.5% (0.5 × HBS) (w/v), respectively.
PEGylation and ultraconcentration of complexes
After DNA complex formation, M-PEG-SPA 5000 (20 mg/ml in DMSO) was added to the solution, gently mixed and the reaction was performed for 1 h at room temperature. The amount of PEG used is indicated as the w/w ratio of PEG/PEI. Usually a weight ratio of 10 was applied: for example, to PEGylate 10 g of DNA complexed with 7.5 g TfPEI (N/P 6.0), 3.75 l M-PEG-SPA 5000 (20 mg/ml) in DMSO were added.
The degree of modification of the primary amino groups of PEI coupled to M-PEG-SPA 5000 can be determined by a ninhydrin assay, analyzing the decrease 603 in free primary amino groups. The assay is based on a protocol we previously decribed, 15 with some minor modifications. In short, triplicates of test samples (containing 5 or 10 g PEI-conjugates or complexes) were diluted with 100 l of reagent B (1.3 mg potassium cyanide dissolved in 2 ml water and 98 ml pyridine) and 75 l of reagent C (2.5 g ninhydrin in 50 ml ethanol). Reagent A (76 g phenol in 24 g ethanol) 15 was omitted in the modified protocol in order to avoid formation of precipitates. After heating for 10 min at 95°C the reaction was stopped by addition of 750 l 60% ethanol and the absorption of the resulting blue solution was measured at 570 nm. For quantification of primary amino groups, glycine was used as a standard. Depending on the presence of transferrin and/or DNA in the sample, ninhydrin readings were adjusted by substraction of values obtained with same amounts of pure transferrin and/or DNA control samples. The ninhydrin assay was found to give the same results with free or DNA-bound PEI conjugates.
For ultraconcentration, PEGylated complexes were applied on VIVA-spin-4000 microconcentrators (100 kDa MW cut-off; VIVA-Science, Lincoln, UK) and concentrated at 4000 g for 2-15 min, until the desired concentration was reached. For example, 8 ml of PEGylated complexes (50 g DNA/ml) were concentrated to 0.5 ml using 1 microconcentrator; approximately 90% of PEGylated complexes (generated in water) could be recovered as measured by UV absorption at 260 nm. The yield of complexes generated in 0.5 × HBS (instead of water) was approximately 60%. In the case of non-PEGylated complexes generated in water, approximately two-thirds of the complexed DNA was lost after concentration.
Determination of particle size of polycation/DNA complexes by laser light scattering Particle size of DNA/PEI and DNA/TfPEI complexes was determined by quasi-elastic (dynamic) light scattering. Complexes were measured at a DNA concentration of 20 g/ml; a volume of 500 l was used for the measurement. Measurements were carried out with a BI90 particle size analyzer (Brookhaven, Holtsville, NY, USA) and are the means of duplicates. Every measurement was carried out in four serial measurements, every 1 min.
Filtration assay for determination of interaction of complexes with plasma DNA (12.8 g in 20 l water were mixed with 9.6 g TfPEI or PEI in 20 l water (N/P 6.0). Complexes were mixed at these high concentrations of DNA and TfPEI (or PEI) in order to obtain larger complexes that are retained by the 200 nm Anopore membrane. After 30 min complexes were PEGylated with 96 g M-PEG-SPA 5000. As determined in control experiments in the absence of plasma, approximately 20% of the DNA of PEGylated complexes and Ͻ1% of non-PEGylated complexes were found in the filtrate (as measured by UV absorption at 260 nm). After 1 h of PEGylation, 2 l of mouse or human citrate plasma in 140 l water were added and incubated for 30 min at 37°C. As a control, 2 l plasma in 180 l water were treated in the same way. The membrane of microcentrifuge tube filters (Whatman, Kent, UK; 200 nm Anopore membrane) was saturated with 500 l bovine serum albumin (1 mg/ml) to reduce unspecific interactions of plasma proteins with the membrane and was washed three times with 500 l of HBS. The mixture of complex and plasma was applied on to the membrane, filtered by centrifugation at 10 000 g ('filtrate' was collected) and washed three times with 500 l HBS. The residue (DNA complex-bound plasma proteins) was eluted with 40 l HBS containing 5% (w/v) SDS ('eluate'). As a control, 2 l plasma in 180 l water were treated in the same way. After addition of non-reducing sample buffer (25% glycerol (w/v); 290 mm Tris pH 6.8; 0.25% SDS (w/v); 0.1 mg/ml bromophenol blue) aliquots of the filtrate and eluate were applied on to a nonreducing 2.5-10% gradient SDS gel according to the Laemmli method and separated at 15 mA for 90 min in a Mini-PROTEAN II electrophoresis cell (Bio-Rad, Hercules, CA, USA). Silver staining of gels was done with a modified method according to Bloom. 47 The filtration assay was also performed using non-PEGylated, small DNA complexes (generated at 20 g DNA/ml). The complexes when incubated with plasma were retained by the filter membrane and showed the same protein pattern bound as the larger complexes (data not shown).
For immunological identification of the proteins a gel was blotted on to a nitrocellulose membrane via semidry blotting (Bio-Rad) with a current of 0.5 mA/cm 2 in 0.01% SDS (w/v), 39 mm glycine and 48 mm Tris for 60 min. Unspecific binding was blocked by incubating the blot in 1% milk powder in TBST (150 mm NaCl; 10 mm Tris pH 8.0; 0.1% Tween 20) for 1 h at room temperature (RT). The blots were incubated for 1 h at RT in the antibody solutions (antibodies were diluted in TBST): goat anti-human complement C3 (fractionated antiserum, Sigma) 1:5000; goat anti-human fibrinogen (fractionated antiserum, Sigma) 1:5000; goat anti-human fibronectin (fractionated antiserum, Sigma) 1:5000; goat anti-human IgM (polyclonal, Jackson Laboratories), dilution 1:1000.
As second antibody a HRP conjugate with rabbit-antigoat IgG, was used (polyclonal, Jackson, West Grove, PA, USA) 1:25 000. After 1 h of incubation at RT the blot was washed several times with TBST and incubated in luminol/enhancer solution and stable peroxide solution (Pharmacia, Uppsala, Sweden) 1/1 (v/v) for 10 min at RT and exposed to luminescence detection film (Hyperfilm-ECL; Amersham, Uppsala, Sweden).
Erythrocyte aggregation assay
Fresh blood from A/J mice was collected and immediately mixed with sodium citrate to a final concentration of 25 mm. Erythrocytes were washed on ice three times in Ringers solution. Two hundred microliters of washed erythrocyte suspension were mixed with the indicated amount of DNA/TfPEI complexes and incubated for 1 h at 37°C in 24-well plates (Nunc, Rochester, NY, USA).
Cell culture and transfections K562 cells (ATCC CCL-243) and Neuro2A cells (ATCC CCL 131) were cultured in Roswell Park Memorial Institute (RPMI) medium 1640/10% fetal calf serum (FCS)/2 mm glutamine/antibiotics. For transfections, 500 000 K562 cells or 25 000 Neuro2A cells per well were plated in 24-well plates (Costar, Acton, MA, USA). Twenty-four hours after transfection cells were harvested and luciferase expression measured as described. 13 Values are given as total light units per transfection and are the means of duplicates (K562) or triplicates (Neuro2A).
Gene transfer in vivo
A/J mice were injected subcutaneously with 2 × 10 6 Neuro2a cells. After 2 weeks, when tumors had reached approximately 10-14 mm in size, transfection complexes were injected into the tail vein. Experiments were carried out at least in triplicates. At 48 h after application animals were killed and tumors and organs were resected. Tissues were submersed in buffer containing 250 mm Tris pH 7.0 and were homogenized with an IKA homogenizer (IKA, Staufen, Germany) and centrifuged at 10 000 g for 10 min. Luciferase activity in the tissue lysates was measured using a Lumat LB9501/16 instrument from Berthold, Bad Wildbad, Germany, from an aliquot of the lysate as described previously. 9 Luciferase instrument background was substracted from each value. Transfection efficiencies are given as total relative light units (RLU) per organ or tumor. The luciferase values of organs and tumors of untreated animals were not distinguishable from the instrument background and р100 RLU per organ. One million RLU correspond to 2 ng luciferase.
Isolation of DNA from blood and plasma Isolation of DNA was performed according to the QIAamp Tissue Kit protocol (Qiagen, Hilden, Germany). To each aliquot (100 l) of blood or plasma, 10 l of heparin (Heparin 'Novo', 1000 IU/ml; Novo Nordisk, Bagsvaerd, Denmark) were added during the initial incubation at 70°C to ensure the quantitative isolation of plasmid DNA (the complexes were shown to dissociate in the presence of heparin). Aliquots of the isolated DNA were put on 0.8% agarose gel and subjected to Southern blot analysis.
Southern blotting
The agarose gel was denatured (1.5 m NaCl, 0.5 m NaOH) for 45 min according to standard protocols, washed with distilled water and rinsed in 1 m Tris/1.5 m NaCl for 30 min. Transfer to nylon membranes (Gene Screen, DuPont, Wilmington, DE, USA; NEF983) was done by capillary transfer in 10 × SSC; DNA was cross-linked to filters by UV radiation.
Hybridization and washing was done as suggested in the DIG High Prime DNA Labeling and Detection Starter Kit II from Boehringer Mannheim (Mannheim, Germany; Catalogue No. 1585614). The filters were prehybridized for 4 h and hybridized overnight with the DIG-labeled probe at 42°C in 50% formamide, 5 × SSC, 0.1% Nlauroylsarcosine, 0.02% SDS, 2% blocking reagent and 100 g/ml yeast t-RNA. The final wash was in 0.5 × SSC, 0.1% SDS at 68°C.
The hybridization probe was generated from plasmid pCMVL 46 by DIG labeling according to the protocol (DIG High Prime DNA Labeling and Detection Starter Kit II; Boehringer Mannheim). Immunological detection was done as described in the kit. The substrate supplied in the kit was replaced with Vistra ECF substrate (Amersham Catalogue No. RPN5785) that can be detected in a Phosphor Imager (Molecular Dynamics, Wayzata, MN, USA). For the quantification of the plasmid DNA, on each agarose gel, different amounts of pCMVL were loaded (5 ng, 500 pg, 50 pg, 5 pg and 0.5 pg, respectively) for direct comparison of the intensities of the bands detected on the blots. Total amounts of DNA in blood and plasma were calculated from the values obtained. The total amount of plasmid DNA in blood and plasma was determined by taking into account that from 100 l of blood approximately 60 l of plasma are obtained. A 2 ml blood volume was assumed for the distribution of complexes in the blood stream.
